Bluejay Diagnostics (BJDX) Accounts Payables (2020 - 2026)

Bluejay Diagnostics has disclosed Accounts Payables across 7 years of filings, most recently posting $1.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.1 million, up 57.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 57.3% YoY), and the FY2025 annual result was $804942.0, up 454.67% from the prior year.
• Accounts Payables came in at $1.1 million for Q1 2026 at Bluejay Diagnostics, up from $804942.0 in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $1.9 million in Q3 2023 to a low of $108817.0 in Q2 2025.
• The 5-year median for Accounts Payables is $443035.0 (2022), against an average of $583017.6.
• Peak annual rise in Accounts Payables reached 454.67% in 2025, while the deepest fall reached 91.57% in 2025.
• Bluejay Diagnostics' Accounts Payables stood at $635818.0 in 2022, then dropped by 22.7% to $491474.0 in 2023, then plunged by 70.47% to $145122.0 in 2024, then soared by 454.67% to $804942.0 in 2025, then jumped by 36.23% to $1.1 million in 2026.
• The last three Accounts Payables figures came in at $1.1 million (Q1 2026), $804942.0 (Q4 2025), and $161162.0 (Q3 2025), per Business Quant data.